Myo-inositol Insulin Resistance Meta-analysis: What the Evidence Says

Quick Answer

Myo-inositol Insulin Resistance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Common clinical complications closely associated with this condition include metabolic disorders such as obesity and insulin resistance (IR). [Duan Mengxue (2026); evidence level 2]
• Indeed, PCOS is responsible for approximately 70% of all anovulatory infertility cases.Furthermore, individuals with PCOS are at an increased lifelong risk of obesity, metabolic syndrome, type 2 diabetes, and coronary artery disease. [Duan Mengxue (2026); evidence level 2]
• Besides diabetes, metformin has found off-label applications, most notably in PCOS and weight management, but also in other areas as cardiovascular diseases, oncology, and neurological disorders. [Russo Michele (2025); evidence level 4]
• Metformin appears to have a synergistic relationship with a healthy gut microbiota environment, as coadministration of metformin with probiotics improved metabolic function in patients with T2DM. [Russo Michele (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For myo-inositol insulin resistance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Duan Mengxue (2026). Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. DOI: 10.3389/fendo.2026.1741509. PMCID: PMC12932251. PMID: 41757236. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12932251/
• Russo Michele (2025). Metformin and Myo-Inositol: A Comparative Analysis. DOI: 10.1159/000549646. PMCID: PMC12721718. PMID: 41269915. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12721718/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.